Background Following publication of the Leuven Intensive Insulin Therapy Trial in 2001,
tight glycemic control became the standard of care in ICUs around the world. Recent studies …

Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and
insulin action. New compounds have been developed for improving glucose‐induced …

Objective: To determine the mid-and long-term efficacy and possible side effects of
laparoscopic sleeve gastrectomy as treatment for morbid obesity. Summary Background …

Background Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide
pharmacological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors …

Type 2 diabetes is a complex meta-bolic disorder characterized by hyperglycemia arising
from a combination of insufficient insulin secretion together with resistance to insulin action …

Objective: To evaluate the efficacy and tolerability of sitagliptin when added to insulin
therapy alone or in combination with metformin in patients with type 2 diabetes. Methods …

GPR40, one of the G protein-coupled receptors predominantly expressed in pancreatic β-
cells, mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. A …

Endothelial cells have a robust capacity to proliferate and participate in angiogenesis, which
underlies the maintenance of intimal layer integrity. We previously showed the presence of …

The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile,
inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of …

OBJECTIVE Glucagon-like peptide-1 (7-36) amide (GLP-1) is cleaved by dipeptidyl
peptidase-4 (DPP-4) to GLP-1 (9-36) amide. We examined whether chemical inhibition or …